Lantheus Holdings, Inc. 0L8.F Stock
Lantheus Holdings, Inc. Price Chart
Lantheus Holdings, Inc. 0L8.F Financial and Trading Overview
Lantheus Holdings, Inc. stock price | 57.52 EUR |
Previous Close | 79.56 EUR |
Open | 81.96 EUR |
Bid | 82.02 EUR x 300000 |
Ask | 82.16 EUR x 300000 |
Day's Range | 81.96 - 81.96 EUR |
52 Week Range | 44.4 - 91.82 EUR |
Volume | 15 EUR |
Avg. Volume | 49 EUR |
Market Cap | 5.6B EUR |
Beta (5Y Monthly) | 0.677464 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 4.34 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32 EUR |
0L8.F Valuation Measures
Enterprise Value | 5.56B EUR |
Trailing P/E | N/A |
Forward P/E | 88.12903 |
PEG Ratio (5 yr expected) | 1.84 |
Price/Sales (ttm) | 5.4535103 |
Price/Book (mrq) | 12.562844 |
Enterprise Value/Revenue | 5.415 |
Enterprise Value/EBITDA | 37.253 |
Trading Information
Lantheus Holdings, Inc. Stock Price History
Beta (5Y Monthly) | 0.677464 |
52-Week Change | 43.60% |
S&P500 52-Week Change | 20.43% |
52 Week High | 91.82 EUR |
52 Week Low | 44.4 EUR |
50-Day Moving Average | 82.25 EUR |
200-Day Moving Average | 67.51 EUR |
0L8.F Share Statistics
Avg. Volume (3 month) | 49 EUR |
Avg. Daily Volume (10-Days) | 9 EUR |
Shares Outstanding | 68.33M |
Float | 66.85M |
Short Ratio | N/A |
% Held by Insiders | 2.80% |
% Held by Institutions | 101.29% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -1.72% |
Operating Margin (ttm) | 9.59% |
Gross Margin | 62.91% |
EBITDA Margin | 14.53% |
Management Effectiveness
Return on Assets (ttm) | 5.39% |
Return on Equity (ttm) | -3.68% |
Income Statement
Revenue (ttm) | 1.03B EUR |
Revenue Per Share (ttm) | 15.01 EUR |
Quarterly Revenue Growth (yoy) | 44.00% |
Gross Profit (ttm) | 581.7M EUR |
EBITDA | 149.28M EUR |
Net Income Avi to Common (ttm) | -17702000 EUR |
Diluted EPS (ttm) | -0.25 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 470.86M EUR |
Total Cash Per Share (mrq) | 6.89 EUR |
Total Debt (mrq) | 586.05M EUR |
Total Debt/Equity (mrq) | 131.54 EUR |
Current Ratio (mrq) | 2.798 |
Book Value Per Share (mrq) | 6.524 |
Cash Flow Statement
Operating Cash Flow (ttm) | 380.02M EUR |
Levered Free Cash Flow (ttm) | -151120128 EUR |
Profile of Lantheus Holdings, Inc.
Country | Germany |
State | MA |
City | Bedford |
Address | 201 Burlington Road |
ZIP | 01730 |
Phone | 978 671 8001 |
Website | https://www.lantheus.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 698 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
Q&A For Lantheus Holdings, Inc. Stock
What is a current 0L8.F stock price?
Lantheus Holdings, Inc. 0L8.F stock price today per share is 57.52 EUR.
How to purchase Lantheus Holdings, Inc. stock?
You can buy 0L8.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lantheus Holdings, Inc.?
The stock symbol or ticker of Lantheus Holdings, Inc. is 0L8.F.
Which industry does the Lantheus Holdings, Inc. company belong to?
The Lantheus Holdings, Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Lantheus Holdings, Inc. have in circulation?
The max supply of Lantheus Holdings, Inc. shares is 68.55M.
What is Lantheus Holdings, Inc. Price to Earnings Ratio (PE Ratio)?
Lantheus Holdings, Inc. PE Ratio is 13.25345600 now.
What was Lantheus Holdings, Inc. earnings per share over the trailing 12 months (TTM)?
Lantheus Holdings, Inc. EPS is 4.34 EUR over the trailing 12 months.
Which sector does the Lantheus Holdings, Inc. company belong to?
The Lantheus Holdings, Inc. sector is Healthcare.